| h-var-9d621130e8 | Circadian Epigenetic Ketone Synchronization Protocol | 0.54 | 0.47 | CLOCK/BMAL1 | proposed | 2026-04-20 | SDA-2026-04-03-gap-debate-20260403-222618-2709aad9 |
| h-var-99256f9f61 | Cerebrospinal Fluid p-tau217-Guided Astrocyte-Derived Extracellular Vesicle Deli | 0.54 | 0.39 | CSF p-tau217 (biomarker), lncRNA-0021, astrocyte-derived ext | promoted | 2026-04-17 | SDA-2026-04-26-gap-pubmed-20260410-150509-76c40dac-debate |
| h-909ba8c750 | Epigenetic Reprogramming Required for Late-Stage Interventions (OSKM) | 0.54 | 0.48 | DNA methylation machinery (DNMTs), H3K27ac modifiers (p300/C | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062045-7a6cf14e |
| h-var-1647fd2642 | Real-time closed-loop transcranial focused ultrasound targeting PV interneurons | 0.54 | 0.71 | PVALB | promoted | 2026-04-21 | SDA-2026-04-03-26abc5e5f9f2 |
| h-c69709f5 | Astrocyte Metabolic Memory Reprogramming | 0.54 | 0.60 | SIRT1 | proposed | 2026-04-12 | SDA-2026-04-04-gap-debate-20260403-222618-e6a431dd |
| hyp_test_3aeaba02 | Test: TREM2 enhances amyloid clearance | 0.54 | 0.30 | TREM2 | archived | 2026-04-04 | test-hypothesis-fixtures-v1 |
| hyp_test_69d36bcc | Test: TREM2 enhances amyloid clearance | 0.54 | 0.30 | TREM2 | archived | 2026-04-04 | test-hypothesis-fixtures-v1 |
| hyp_test_51bcc306 | Test: TREM2 enhances amyloid clearance | 0.54 | 0.30 | TREM2 | archived | 2026-04-04 | test-hypothesis-fixtures-v1 |
| hyp_test_fd653a9e | Test: TREM2 enhances amyloid clearance | 0.54 | 0.30 | TREM2 | archived | 2026-04-04 | test-hypothesis-fixtures-v1 |
| hyp_test_59e50f48 | Test: TREM2 enhances amyloid clearance | 0.54 | 0.30 | TREM2 | archived | 2026-04-04 | test-hypothesis-fixtures-v1 |
| h-641d1459da | NRF2 pathway activation to reduce mutant huntingtin aggregates and oxidative str | 0.54 | 0.60 | NFE2L2 | proposed | 2026-05-01 | SDA-2026-05-01-gap-test-20260425-224949 |
| h-57b37c06d6 | Low-Intensity tFUS Modulation of EC-DG/EC-CA1 Perforant Path Synaptic Function | 0.54 | 0.58 | Piezo1 (preclinical validation only); BDNF/TrkB pathway | proposed | 2026-04-28 | SRB-2026-04-28-h-var-b7e4505525 |
| h-923e06cc90 | Cross-Seeding: Gut Microbiome-Derived Bacterial Curli and Fungal Amyloid Synergi | 0.54 | 0.60 | TLR2, TLR1, IRF5, IRF4, CsgA, csgABC operon | proposed | 2026-04-26 | SDA-2026-04-26-gap-20260425-225305 |
| h-8a1a418d72 | Soluble CX3CL1 cleavage by ADAM proteases disengages fractalkine signaling, remo | 0.54 | 0.62 | CX3CL1, CX3CR1, ADAM10, ADAM17 | proposed | 2026-04-22 | SDA-2026-04-02-gap-synaptic-pruning-microglia |
| h-a0a251cfcf | H5: Olfactory System as a Toxicant Funnel into Layer II | 0.54 | 0.48 | NLRP3, CX3CR1, TLR4 | proposed | 2026-04-22 | SDA-2026-04-02-gap-ec-layer2-vulnerability |
| h-10ac959b07 | N-acetylation Deficiency as Novel Metabolic Vulnerabilities in Sporadic ALS | 0.54 | 0.62 | NAA10, NAA20, NAA80 | proposed | 2026-04-22 | SDA-2026-04-02-gap-2026-04-01-gap-006 |
| h-6298061b6e | circHomer1a Restoration as Neuroprotective Strategy in Synaptic Decline | 0.54 | 0.68 | circHomer1a, miR-1961, HOMER1 | proposed | 2026-04-22 | SDA-2026-04-02-gap-2026-04-01-gap-006 |
| h-99dd982b52 | Transient OCT4/SOX2/KLF4/c-MYC Expression Reverses Epigenetic Age and Restores V | 0.54 | 0.65 | OCT4/SOX2/KLF4/c-MYC (OSKM) | proposed | 2026-04-22 | SDA-2026-04-04-gap-20260404-060512 |
| h-2a43bfc5b1 | TAM Receptor (MERTK/AXL) Cross-Regulation | 0.54 | 0.52 | MERTK, AXL, TYRO3, PROS1 (Protein S), GAS6 | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-062118-e3613755 |
| h-6ae3f31128 | H6: Epigenetic Reset via APOE4→APOE3 Conversion Reverses Senescence | 0.54 | 0.45 | APOE; HDAC1; EZH2 | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062101-5d7b9dc0 |
| h-cbd5cd6b7f | BAG3-Mediated Hsp70 Substrate Redistribution | 0.54 | 0.52 | HSPA1A/Hsp70, BAG3 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062150-a6cc7467 |
| h-389692c80b | P2Y6R activation by UDP from damaged neurons drives microglial phagocytosis and | 0.54 | 0.58 | P2RY6 | proposed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062052-946439a8 |
| h-0d030c455b | Systemic IL-6–STAT3–Hepatic C3 Axis and BBB-Mediated Complement Translocation | 0.54 | 0.42 | IL6; STAT3; C3 | proposed | 2026-04-21 | SDA-2026-04-08-gap-pubmed-20260406-062128-afe67892 |
| h-edfd6c89 | Dual-Phase Medium-Chain Triglyceride Intervention | 0.54 | 0.70 | HMGCS2/CPT1A | promoted | 2026-04-12 | SDA-2026-04-04-gap-debate-20260403-222618-e6a431dd |
| h-var-93e3ef09b3 | Microglial Exosome-Mediated Tau Propagation | 0.54 | 0.78 | MAPT | proposed | 2026-04-12 | SDA-2026-04-03-26abc5e5f9f2 |
| h-8986b8af | Lysosomal Membrane Repair Enhancement | 0.54 | 0.62 | CHMP2B | debated | 2026-04-02 | sda-2026-04-01-gap-011 |
| h-5669af0f | Ferroptosis as Disease-Modifying Amplifier | 0.54 | 0.55 | | proposed | 2026-04-18 | SDA-2026-04-18-gap-debate-20260417-032952-48bdcbea |
| h-ebfa8ea3 | ABCA7-TREM2 Co-Targeting for Microglial Lipid Handling | 0.54 | 0.55 | ABCA7 + TREM2 (combinatorial) | proposed | 2026-04-14 | SDA-2026-04-14-gap-pubmed-20260410-180532-e8930cb8 |
| h-62e56eb9 | Glymphatic System-Enhanced Antibody Clearance Reversal | 0.54 | 0.65 | AQP4 | debated | 2026-04-02 | sda-2026-04-01-gap-008 |
| h-c98263c726 | Excitatory/Inhibitory Balance Reversal via Somatostatin Interneuron Rescue | 0.54 | 0.52 | SST | proposed | 2026-04-28 | SDA-2026-04-28-gap-methodol-20260427-041425-9e73b245 |
| hyp_test_490ced0b | Test: TREM2 enhances amyloid clearance | 0.54 | 0.28 | TREM2 | proposed | 2026-04-17 | test-hypothesis-fixtures-v1 |
| h-e064f134 | BMP4 Pathway Inhibition for Oligodendrocyte Myelination Support | 0.54 | 0.50 | BMP4 and BMPR1A | proposed | 2026-04-04 | SDA-2026-04-03-gap-seaad-v2-20260402032945 |
| h-758b4994eb | Synaptic Vulnerability Window Temporal Targeting: Transient SPP1 Blockade | 0.54 | 0.52 | SPP1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062118-2cdbb0dd |
| h-01b8a985c4 | CD36 Acts as Primary Aβ Oligomer Sensor on Perivascular Macrophages, Triggering | 0.54 | 0.55 | SPP1 | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-062118-5e49e14f |
| h-8ebce483d2 | Transient Chaperone Priming Prior to Seed Inoculation Prevents Propagation by Re | 0.54 | 0.62 | HSF1, NFE2L2 (NRF2), HSPA1A, DNAJB1 | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062052-28cbc764 |
| h-b36986e26d | Entorhinal Cortex (EC)-Hippocampus Closed-Loop Interface Restores Layer-Specific | 0.54 | 0.52 | RELN/GRIA1 | proposed | 2026-04-28 | SRB-2026-04-28-h-var-e95d2d1d86 |
| h-c1aec6a4 | Neuron-Specific Expression of Autophagy Inhibitory Phosphatases (PP2A/Bβ1) | 0.54 | 0.55 | PPP2R2B, ULK1 complex | proposed | 2026-04-26 | SDA-2026-04-07-gap-pubmed-20260406-062212-ca78691c |
| h-94e73015 | CSF1R Partial Agonism Combined with TREM2 Activation for ALS Neuroprotection | 0.54 | 0.58 | CSF1R Partial | proposed | 2026-04-25 | SDA-2026-04-17-gap-microglial-subtypes-pharmaco-202604170000 |
| h-5d68a7d2 | Microglial TREM2 Activation to Enhance Synaptic Pruning Regulation | 0.53 | 0.65 | Microglial TREM2 | proposed | 2026-04-25 | SDA-2026-04-16-frontier-connectomics-84acb35a |
| h-0a1650e6 | NFκB/C1Q SASP Modulation for Synaptic Protection | 0.53 | 0.58 | C1Q | proposed | 2026-04-17 | SDA-2026-04-26-gap-pubmed-20260410-181340-8acb24dc-debate |
| h-analogy-bb6d7fb1 | Closed-loop orexin receptor modulation to entrain circadian glymphatic clearance | 0.53 | 0.40 | HCRTR1/HCRTR2 (orexin receptor genes) | active | 2026-04-28 | |
| h-959a4677 | Blood-Brain Barrier SPM Shuttle System | 0.53 | 0.70 | TFRC | debated | 2026-04-02 | sda-2026-04-01-gap-014 |
| h-ae4a2281 | PLIN2 (Perilipin-2) Degradation via Autophagy Activation to Clear Disease-Associ | 0.53 | 0.55 | PLIN2/NEDD4L (Lipophagy) | proposed | 2026-04-25 | SDA-2026-04-16-frontier-lipidomics-dcdbc360 |
| h-6c83282d | Gut Barrier Permeability-α-Synuclein Axis Modulation | 0.53 | 0.60 | CLDN1, OCLN, ZO1, MLCK | proposed | 2026-04-02 | SDA-2026-04-01-gap-20260401-225155 |
| h-5afacdfe | Lactate/Pyruvate Ratio Dynamics in CSF as a Neuroinflammation-Metabolism Interfa | 0.53 | 0.60 | LDHA, TREM2 | proposed | 2026-04-12 | SDA-2026-04-04-SDA-2026-04-04-gap-debate-20260403-222618-c69 |
| h-0f025d94 | PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Micro | 0.53 | 0.50 | PLCG2 | proposed | 2026-04-16 | SDA-2026-04-01-gap-001 |
| h-test-full-8d254307 | EV-Mediated Epigenetic Reprogramming | 0.53 | 0.60 | EVs/miRNAs | proposed | 2026-04-11 | sda-2026-04-12-ev-ad-biomarkers |
| h-7dfdc5d7 | Mitochondrial-Cytokine Axis Modulation | 0.53 | 0.70 | Mitochondrial respiratory complexes and inflammatory cytokin | promoted | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-var-b7e8e12838 | TBK1 Loss Drives Motor Neuron Death Through Impaired Mitophagy and Metabolic Col | 0.53 | 0.34 | TBK1 → OPTN / p62 / FIP200 / mitophagy machinery | proposed | 2026-04-27 | SDA-2026-04-26-gap-20260425215446 |
| h-a947032c | Glucose-Ketone Metabolic Switch Timing | 0.53 | 0.30 | GLUT1/GLUT3/MCT1/MCT2 | proposed | 2026-04-16 | SDA-2026-04-03-gap-debate-20260403-222618-2709aad9 |